Sputnik Light can become a major booster for those vaccinated with inactivated Chinese COVID vaccines globally
PR94600
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese COVID vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
MOSCOW, Feb. 28, 2022 /PRNewswire=KYODO JBN/ --
There are 2 billion people who have received inactivated Chinese vaccines in
the country and globally. As China has just authorized mix & match boosting
with domestic vaccines, the Russian one-shot Sputnik Light vaccine can become a
universal booster for those vaccinated with Chinese vaccines in other countries
around the world to strengthen and lengthen their protection against COVID.
Regulatory authorities of China have approved the mixing of domestic
inactivated vaccines against COVID (in particular, Sinovac and Sinopharm) and
use of a different vaccine, including adenoviral-based, as booster shot
providing yet another confirmation of the efficacy of mix & match approach
pioneered by the Russian Sputnik V vaccine in creating a stronger and more
durable immunity, including against the Omicron variant.
Vaccines produced by Chinese companies (Sinovac and Sinopharm) are widely used
with over 4.7 billion doses supplied in China and globally[1]. While China's
State Council has authorized mix & match boosting only with domestic
vaccines[2], the Russian one-shot Sputnik Light vaccine (the first component of
Sputnik V) can become a solution for boosting those initially vaccinated with
Chinese vaccines in other countries around the world.
Sputnik Light has already shown strong results used as a booster in mix & match
trials, including for inactivated vaccines. For example, the study conducted in
Argentina on Sputnik Light combination with other vaccines has shown that
antibody and T-cells response elicited by Sputnik Light as a booster to
inactivated Sinopharm vaccine is 10x higher vs two shots of Sinopharm. The
study also has demonstrated that each "vaccine cocktail" combination with
Sputnik Light with other vaccines like Moderna, AstraZeneca and Cansino had
provided a higher antibody titer on the 14th day after administering a second
dose when compared to original homologous (same vaccine as first and second
dose) regimens of each of the vaccines. Using Sputnik Light in combinations
with all other vaccines showed high safety profile with no serious adverse
events following the vaccination in any combinations.
The heterogeneous boosting approach ("vaccine cocktail" using human adenovirus
serotype 26 as the first component and human adenovirus serotype 5 as the
second component) pioneered by the Russian Gamaleya Center is at the core of
Sputnik V, the world's first registered vaccine against coronavirus. This
approach had proven successful in creating a longer and more durable immunity
against the coronavirus as demonstrated by the real-world data from Hungary,
San Marino, Argentina, Serbia, Bahrain, Mexico, UAE and other countries.
To date Sputnik Light has been approved in more than 30 countries with a total
population of over 2.5 billion and Sputnik V – in 71 countries with a total
population of over 4 billion people.
Sputnik V creates stronger and longer lasting immune response against COVID
(including the Omicron variant) than many other vaccines, which is further
strengthened by Sputnik Light booster. A unique comparative study[3] conducted
at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a
team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of
the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya
Center has shown that Sputnik V vaccine demonstrates more than 2 times higher
titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2
doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3
months after vaccination).
The study was conducted in the equal laboratory conditions on comparable sera
samples from individuals vaccinated with Sputnik V and Pfizer with a similar
level of IgG antibodies and virus neutralizing activity (VNA) against Wuhan
variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus
neutralizing activity against Omicron as compared to reference Wuhan variant
than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold
reduction for Pfizer vaccine).
Based on the data collected by the Spallanzani Institute and results of
previous studies, mix & match boosting with Sputnik Light is the best solution
to increase other vaccines' efficacy and extend the booster protection period
as optimal adenoviral platform configuration provides better protection against
Omicron and other mutations.
Sputnik Light and Sputnik V and have been developed using a safe technology
that has been widely studied for over 30 years and have not been associated
with rare serious side effects such as myocarditis or pericarditis.
The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated
in more than 30 studies and real-world data publications from more than 10
countries.
Sputnik V and Sputnik Light can be stored in a conventional refrigerator at +2
+8 degrees C for 6 months, making them available globally, including in remote
territories, without any need to invest in additional cold-chain infrastructure.
[1]
[2]
[3] https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1
Logo -
https://mma.prnewswire.com/media/1698158/Russian_Direct_Invest_Fund_Logo.jpg
Source: The Russian Direct Invest Fund (RDIF)
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。